No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 2 | N/A | 0 | 0 | 0 | N/A | N/A | N/A |
| Operating profit | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | €m | -0 | N/A | -3 | -1 | -0 | N/A | N/A | N/A |
| EPS reported | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
bonyf N.V. is a Belgian firm dedicated to the research, development, manufacturing, and distribution of a diverse range of oral and dental healthcare products. Its specialized offerings include PerioTabs, a brushing solution crafted for gums, teeth, and dental implants to mitigate conditions such as gingivitis, periodontitis, peri-mucositis, and peri-implantitis. Another key product is AphtoFix, a film-forming cream designed for the localized treatment of mouth ulcers. The company provides an extensive line of denture care items, featuring OlivaFix and Superior denture adhesive creams, alongside NitrAdine disinfecting denture tabs for hygiene. For repairs, bonyf offers Denture Repair-fix, an immediate solution for fractured dentures or detached teeth, and Fixobridge, a ready-to-use cement for reattaching dislodged crowns, inlays, and bridges. Complementing these are denture relining cushions for improving the fit of ill-fitting dentures, effervescent denture cleanser tabs, and Cavifix, a synthetic resin-based material for temporarily sealing new cavities and repairing lost fillings. Beyond general dental care, bonyf N.V. extends into orthodontic solutions with NitrAdine Ortho & Junior disinfecting tabs, formulated to clean and sanitize removable orthodontic appliances. Furthermore, its portfolio includes wound care products like HeelFix and FingerFix paste dressings, specifically designed to address cracked and chapped skin on the feet and hands. Established in 1979, the company's corporate headquarters are located in Gent, Belgium.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
bonyf N.V. is a Belgian firm dedicated to the research, development, manufacturing, and distribution of a diverse range of oral and dental healthcare products. Its specialized offerings include PerioTabs, a brushing solution crafted for gums, teeth, and dental implants to mitigate conditions such as gingivitis, periodontitis, peri-mucositis, and peri-implantitis. Another key product is AphtoFix, a film-forming cream designed for the localized treatment of mouth ulcers. The company provides an extensive line of denture care items, featuring OlivaFix and Superior denture adhesive creams, alongside NitrAdine disinfecting denture tabs for hygiene. For repairs, bonyf offers Denture Repair-fix, an immediate solution for fractured dentures or detached teeth, and Fixobridge, a ready-to-use cement for reattaching dislodged crowns, inlays, and bridges. Complementing these are denture relining cushions for improving the fit of ill-fitting dentures, effervescent denture cleanser tabs, and Cavifix, a synthetic resin-based material for temporarily sealing new cavities and repairing lost fillings. Beyond general dental care, bonyf N.V. extends into orthodontic solutions with NitrAdine Ortho & Junior disinfecting tabs, formulated to clean and sanitize removable orthodontic appliances. Furthermore, its portfolio includes wound care products like HeelFix and FingerFix paste dressings, specifically designed to address cracked and chapped skin on the feet and hands. Established in 1979, the company's corporate headquarters are located in Gent, Belgium.
